BioRestorative Therapies, Inc. Common Stock (NV)
BRTX XNASAbout BioRestorative Therapies, Inc. Common Stock (NV)
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $23.2K | $-2,154,405 | $-0.12 |
| FY 2025 | $359.7K | $-14,241,975 | $-1.58 |
| Q3 2025 | $11.8K | $-3,038,277 | $-0.33 |
| Q2 2025 | $303.3K | $-2,656,263 | $-0.30 |
Earnings & Analyst Ratings
TickerDaily Coverage
Get BRTX Alerts
Stay ahead with breaking news, price alerts, and expert analysis on BioRestorative Therapies, Inc. Common Stock (NV).